Invion Limited, a clinical-stage drug development company, develops treatments for chronic inflammatory and autoimmune diseases in Australia and the United States. Its drug candidates in phase II clinical trials include INV102, a beta blocker to treat chronic inflammatory airway diseases, such as asthma and chronic obstructive pulmonary disease; and INV104, a leukotriene receptor antagonist that reduces inflammation, constriction of the airways, and build-up of mucus in the lungs. The company has a research and development alliance agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers. Invion Limited is based in East Kew, Australia.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 3 9081 6005
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.88 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Invion (ASX:IVX) Frequently Asked Questions
What is Invion's stock symbol?
Invion trades on the ASX under the ticker symbol "IVX."
Has Invion been receiving favorable news coverage?
Media coverage about IVX stock has been trending somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Invion earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Invion.
Who are some of Invion's key competitors?
Some companies that are related to Invion include Supreme Cannabis (FIRE), Benchmark (BMK), Flowr (FLWR), CannTrust (TRST), ICC Labs (ICC), Shield Therapeutics (STX), Amryt Pharma (AMYT), WeedMD (WMD), Althea Group (AGH), Probiotec (PBP), Auscann Group (AC8), ESSA Pharma (EPI), Harvest One Cannabis (HVT), Delta 9 Cannabis (NINE) and Biosyent (RX).
What other stocks do shareholders of Invion own?
Who are Invion's key executives?
Invion's management team includes the folowing people:
- Dr. Gregory Royce Collier, MD, CEO & Exec. Director (Age 60)
- Ms. Melanie Farris, Head of Operations & Company Sec.
- Dr. Mitchell Glass, Exec. VP of R&D, Chief Medical Officer and Exec. Director (Age 66)
- Mr. Tom Coogan, Consultant
- Dr. Dean Naylor, Head of Intellectual Property Devel.
What is Invion's stock price today?
One share of IVX stock can currently be purchased for approximately A$0.01.
How big of a company is Invion?
What is Invion's official website?
How can I contact Invion?
The company can be reached via phone at 61 3 9081 6005.
MarketBeat Community Rating for Invion (ASX IVX)
MarketBeat's community ratings are surveys of what our community members think about Invion and other stocks. Vote "Outperform" if you believe IVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
